NTRK1 and neoplasm: 3-[4-(dimethylamino)benzylidenyl]indolin-2-one (SU4312), initially designed as a multi-target receptor tyrosine kinase inhibitor [9], is found to inhibit tumor angiogenesis by blocking VEGFR [10].